Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units

This is a multicentre, cluster randomized study comparing two parallel groups:

• Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
• Control group: nursing homes whose residents continue to benefit from usual care In each group, 1000 elderly subjects aged over 60 years without documented diagnosis of dementia will be included and monitored for a period of 18 months.

Information about the main and secondary aims will be collected monthly through online questionnaires.

Inclusion criteria

• Residents of both sex, aged 60 years or over
• Residents living in a nursing home participating in the study
• Residents living in the nursing home for 30 days or more
• Residents without diagnosed and documented dementia, identified as follows:

• residents not identified by the French Healthcare system as suffering from dementia (ALD 15)
• residents not benefiting from a specific care program or a specialized follow-up for dementia
• residents for whom there is no appropriate investigation for dementia diagnosis in medical records
• residents not taking specific drugs for dementia (Cholinesterase inhibitors and/or Memantine)
• Residents and their GP having received information about the study
• Residents and their GP having expressed their agreement to participate in the study

Exclusion criteria

• Residents aged less than 60 years
• Residents not living in a nursing home participating in study
• Residents living in nursing home for less than 30 days
• Residents with diagnosed and documented dementia, identified as follows:

• residents Identified by the French Healthcare system as suffering from dementia (ALD 15)
• residents benefiting from specific care programme or specialized follow-up for dementia
• residents for whom there is appropriate investigation for dementia diagnosis in medical records
• residents taking specific drugs for dementia (Cholinesterase inhibitors and/or Memantine)
• Residents and/or their GP who received no information about the study
• Residents and/or their GP having expressed their opposition to participate in the study